E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Crohn's Disease |
Morbo di Crohn |
|
E.1.1.1 | Medical condition in easily understood language |
Crohn's Disease |
Morbo di Crohn |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013099 |
E.1.2 | Term | Disease Crohns |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this study are to determine the efficacy and safety of multiple doses of ABT-494 versus placebo and to assess the pharmacokinetics (PK) of ABT-494 following oral administration in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to anti-TNF therapy. |
Gli obiettivi di questo studio sono determinare l’efficacia e la sicurezza di dosi multiple di ABT-494 rispetto al placebo e valutare la farmacocinetica (PK) di ABT-494 dopo la somministrazione orale in soggetti con morbo di Crohn da moderatamente a gravemente attivo con una storia di risposta inadeguata o intolleranza alla terapia anti-TNF. |
|
E.2.2 | Secondary objectives of the trial |
Not Applicable |
Non applicabile |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Male or female ≥ 18 and ≤ 75 years of age at Baseline -Diagnosis of Crohn's disease (CD) for at least 90 days -CDAI ≥ 220 and ≤ 450 -Subject inadequately responded to or experience intolerance to previous treatment with an anti-TNF agent (e.g., infliximab, adalimumab, or certolizumab pegol). |
-Uomo o donna ≥18 e ≤75 anni di età al basale. -Diagnosi di morbo di Crohn (CD) per almeno 90 giorni. -CDAI ≥220 e ≤450. -Il soggetto ha risposto in modo inadeguato o ha manifestato intolleranza a un precedente trattamento con un agente anti TNF (ad esempio, infliximab, adalimumab o certolizumab pegol). |
|
E.4 | Principal exclusion criteria |
-Subject with ulcerative colitis (UC), collagenous colitis or indeterminate colitis -Subject who has had surgical bowel resections in the past 6 months or is planning resection -Subjects with an ostomy or ileoanal pouch -Subject with bowel stricture or abdominal or peri-anal abcess -Subject who has short bowel syndrome -Subject with chronic recurring infections or active Tuberculosis (TB) |
-Soggetto con diagnosi attuale di colite ulcerosa (CU), colite collagenosa o colite indeterminata -Soggetto che è stato sottoposto a una resezione intestinale chirurgica negli ultimi 6 mesi o ha in programma una resezione -Soggetto con stomia, sacchetto ileoanale. -Soggetto con ascesso addominale o perianale. -Soggetto affetto da sindrome da intestino corto. -Soggetto con infezioni ricorrenti croniche o TBC attiva |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The co-primary endpoints are: -Proportion of subjects who achieve endoscopic remission at Week 12/16. -Proportion of subjects who achieve clinical remission at Week 16. |
Gli endpoint co-primari sono: -Percentuale di soggetti che raggiungono la remissione endoscopica alla settimana 12/16. -Percentuale di soggetti che raggiungono la remissione clinica alla settimana 16.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
week 12/16 |
settimana 12/16 |
|
E.5.2 | Secondary end point(s) |
- Proportion of subjects who achieve CDAI < 150 at Week 16. - Proportion of subjects with decrease in CDAI ≥ 70 points from Baseline at Week 16. - Proportion of subject who achieve remission at Week 52. |
-Percentuale di soggetti che raggiungono CDAI <150 alla settimana 16. -Percentuale di soggetti con riduzione di CDAI ≥70 punti dal basale alla settimana 16. -Percentuale di soggetti che raggiungono la remissione alla settimana 52.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Duration of the study. |
Durata dello studio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 65 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
Czech Republic |
Denmark |
France |
Germany |
Hungary |
Israel |
Italy |
Netherlands |
New Zealand |
Norway |
Poland |
Puerto Rico |
Romania |
Slovakia |
Spain |
Sweden |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LSLV or the last follow-up contact, whichever is longer. |
LSLV o ultimo contatto di follow-up, quale dei due è più lungo. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |